Featured,Spotlight Stock MYND Life Sciences Acquires Rights to Use Psychedelics to Treat Alzheimer’s Disease By Dennis Mutua December 20, 2021 Neuro-pharmaceutical drug development company focusing on advancing psychedelic medicine which mental illnesses MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) announced having successfully acquired the rights, interest and title...
Featured,Spotlight Stock First Ever Psychedelic Research and Therapy Center Launched in Texas By Dennis Mutua December 17, 2021 Researchers from Dell Medical School at the University of Texas Austin have launched a Center for Psychedelic Research and Therapy in Austin, Texas as part of the institution’s efforts to use psychedelics to treat various mental...
Featured,Spotlight Stock Cybin Granted Notice of Allowance for CYB004 in Treatment of Anxiety Disorder by USPTO By Dennis Mutua December 16, 2021 Biopharmaceutical company specializing on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols Cybin Inc. (NYSE: CYBN) announced been awarded a notice of allowance by the United States P...
Featured,Trends & Articles DEA Revises 2022 Production Quotas for Psychedelics Upwards By Dennis Mutua December 13, 2021 The Drug Enforcement Agency (DEA) has revised upwards its 2022 production quotas for illicit controlled substances including MDMA, DMT and psilocybin for research purposes. This was communicated through a notice recently published...
Featured,Trends & Articles DEA and NIDA Supports White House Plan to Streamline Research on Marijuana and Psychedelics By Dennis Mutua December 08, 2021 The Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA) announced that they are in full support of a proposal by White House to streamline the research process on Schedule I drugs including mariju...
Featured,Spotlight Stock University of Washington Testing Psilocybin on Health Workers Affected by the Pandemic By Dennis Mutua December 06, 2021 Researchers from University of Washington (UW) are planning to administer psilocybin doses on health workers affected by the COVID19 pandemic with an aim of conducting a new clinical trial which is testing a combination of psilocy...
Featured,Spotlight Stock Sunstone Therapies Unveils Initiative to Accelerate Psychedelic Therapy For Oncology Patients By Dennis Mutua December 02, 2021 Biopharmaceutical company focusing on easing and pain and suffering associated with cancer Sunstone Therapies has unveiled an initiative to accelerate and scale safe psychedelic therapy aimed at addressing the mental and emotional...
Featured,Spotlight Stock Numinus Granted Conditional Approval to Graduate its Listing to TSX By Dennis Mutua November 29, 2021 Mental healthcare company developing and delivering evidence-based psychedelics therapies Numinus Wellness Inc. (TSXV: NUMI) announced having received a conditional approval from the Toronto Stock Exchange (TSX) to graduate its li...